Sign in

You're signed outSign in or to get full access.

BT

BioXcel Therapeutics, Inc. (BTAI)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 showed mixed results: EPS beat consensus while revenue missed, as BioXcel continued to minimize commercial spend and focus on late-stage development. Net loss narrowed to $7.3M with EPS of -$1.50 vs -$13.89 y/y, and cash was $31.0M at March 31, 2025 .
  • EPS beat: -$1.50 actual vs -$3.04 consensus; Revenue miss: $0.17M actual vs $0.35M consensus. Management did not issue financial guidance, maintaining focus on clinical milestones (topline SERENITY At-Home in 2H 2025) (consensus values marked with asterisks; see S&P Global disclaimer). Actuals from press release .
  • Key operational catalyst: SERENITY At-Home Phase 3 fully enrolled, DSMB meeting scheduled mid-May; topline data targeted for 2H 2025 to support a potential sNDA for IGALMI at-home use .
  • Risk balance: continued going-concern language and indebtedness in disclosures, partially offset by capital actions (reverse split; $14M equity raise) and Nasdaq bid-price compliance regained in February 2025 .

What Went Well and What Went Wrong

What Went Well

  • SERENITY At-Home pivotal trial fully enrolled; >165 patients dosed and >115 with multiple doses; DSMB in mid-May; topline data expected 2H 2025. CEO: “We are pleased to have achieved this major milestone … excited by the opportunity to expand the market potential of IGALMI” .
  • Operating discipline: R&D cut to $4.6M (vs $11.4M y/y) and SG&A to $5.7M (vs $13.3M y/y) as reprioritization actions flowed through; net loss narrowed to $7.3M (vs $26.8M y/y) .
  • Regulatory de-risking: FDA closed inspection of a TRANQUILITY II site with “Voluntary Action Indicated,” supporting data reliability for the Alzheimer’s program .

What Went Wrong

  • Commercial traction remains limited: IGALMI net revenue fell to $0.17M from $0.58M y/y and down sequentially from $0.37M in Q4 2024; company continues “minimal commercial resources” posture .
  • Liquidity/going-concern overhang: disclosures flag substantial doubt about ability to continue as a going concern and cite significant indebtedness and covenant obligations .
  • No financial guidance and no Q1 2025 earnings call transcript available through our sources, limiting visibility on near-term revenue/OpEx cadence and commercial strategy inflection points (no Q1 call found; latest call was Q3 2024) .

Financial Results

Quarterly trend (oldest → newest)

MetricQ3 2024Q4 2024Q1 2025
IGALMI Net Revenue ($USD Millions)$0.214 $0.366 $0.168
Cost of Goods Sold ($USD Millions)$1.170 $0.832 $0.014
R&D Expense ($USD Millions)$5.101 $5.901 $4.554
SG&A Expense ($USD Millions)$7.683 $4.094 $5.699
Net Loss ($USD Millions)$13.650 $10.859 $7.254
EPS (Basic & Diluted) ($)$(0.32) $(3.57) $(1.50)

Note: Q3 2024 figures were reported prior to the February 2025 reverse split; per-share comparability to subsequent quarters may be affected .

Year-over-year comparison (Q1 2024 vs Q1 2025)

MetricQ1 2024Q1 2025
IGALMI Net Revenue ($USD Millions)$0.582 $0.168
R&D Expense ($USD Millions)$11.401 $4.554
SG&A Expense ($USD Millions)$13.264 $5.699
Net Loss ($USD Millions)$26.791 $7.254
EPS (Basic & Diluted) ($)$(13.89) $(1.50)

Consensus vs Actuals (key headline items)

MetricQ1 2025 ConsensusQ1 2025 Actual
Revenue ($USD Millions)$0.350*$0.168
Primary EPS ($)$(3.04)*$(1.50)

Values with asterisk (*) retrieved from S&P Global.

Cash and Liquidity

MetricQ3 2024Q4 2024Q1 2025
Cash & Cash Equivalents ($USD Millions)$40.387 $29.854 $31.013

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
SERENITY At-Home topline timing20252H 2025 2H 2025 Maintained
SERENITY At-Home DSMB timingQ2 2025DSMB planned DSMB scheduled mid-May More specific
SERENITY At-Home enrollmentQ1 202563% enrolled (127 pts) Enrollment complete; >165 dosed; >115 multi-dose Progressed
TRANQUILITY In-Care status2025Plans advanced after FDA feedback Advancing plans for initiation Maintained/Advancing
Financial guidance (revenue, margins, OpEx)2025Not providedNot providedNo change

Earnings Call Themes & Trends

TopicQ3 2024 (previous)Q4 2024 (previous)Q1 2025 (current)Trend
R&D execution (SERENITY)First patient randomized; 9–12 month duration; 26+ sites planned 63% enrolled (127 pts); 24 sites open Enrollment complete; DSMB mid-May; topline 2H 2025 Improving cadence toward data
Regulatory/legal—FDA closure of TRANQUILITY II site inspection highlighted in Q4 PR set FDA site inspection closed, “Voluntary Action Indicated,” supports data integrity De-risking
Financing/liquidityExploring options; focus on data readout $14M equity financing announced/closed Mar 2025 Cash $31.0M at 3/31/25; going-concern language persists Mixed (added cash; risk remains)
CommercializationMinimal commercial resources; maintain IGALMI availability Continue supplying IGALMI with minimal commercial support Continue supplying IGALMI with minimal commercial resources Flat (limited push)
Alzheimer’s (TRANQUILITY)FDA protocol feedback received Plans advanced post-FDA feedback Advancing plans for trial initiation Steady progress

Management Commentary

  • “We are pleased to have achieved this major milestone in our first trial of BXCL501 in the at-home setting… We look forward to a data readout expected in the second half of this year and are excited by the opportunity to expand the market potential of IGALMI” — Vimal Mehta, Ph.D., CEO .
  • On commercialization stance: “The Company is continuing to supply IGALMI to patients and providers, and build brand awareness, with minimal commercial resources.” .
  • On TRANQUILITY II data reliability: “We believe the reliability of data from its TRANQUILITY II Phase 3 trial… [is] further supported by the FDA closure of its site inspection… ‘Voluntary Action Indicated’” .

Q&A Highlights

  • No Q1 2025 earnings call transcript was available via our sources. The most recent transcript (Q3 2024) emphasized: enrollment ramp and 9–12 month SERENITY timeline ; allowance of rescue meds in SERENITY and tracking as surrogate of placebo inefficacy ; strategy to strengthen the balance sheet to reach data readout ; and the potential for SERENITY At-Home to unlock partnership opportunities .

Estimates Context

  • Q1 2025 vs consensus: EPS beat (actual -$1.50 vs -$3.04*) and revenue miss (actual $0.168M vs $0.350M*). Continued minimal commercial investment likely constrained near-term sales while cost controls supported EPS outperformance (consensus values marked with asterisks; see S&P Global disclaimer). Actuals from press release .
  • Recent quarters: Q4 2024 also showed EPS beat (actual -$3.56 vs -$6.94*) and revenue miss (actual $0.366M vs $0.718M*) (consensus values marked with asterisks; see S&P Global disclaimer). Actuals from press releases .
  • Estimate alignment: With topline SERENITY At-Home data due 2H 2025, we expect models to remain focused on R&D cadence and potential label expansion scenarios rather than material near-term revenue inflection (given stated minimal commercial resources) .

Values with asterisk (*) retrieved from S&P Global.

KPIs (Clinical and Operating)

KPIQ4 2024Q1 2025 (Mar 7)Q1 2025 (May 12)
SERENITY At-Home enrollment127 enrolled; 24 sites open 67 enrolled; 23 sites open Enrollment complete; >165 dosed; >115 multi-dose
DSMBPlanned Planned Scheduled mid-May
Topline timing2H 2025 2H 2025 2H 2025
IGALMI Net Revenue ($M)$0.366 —$0.168 (Q1)
Cash & Equivalents ($M)$29.854 —$31.013

Key Takeaways for Investors

  • Near-term stock driver is SERENITY At-Home: fully enrolled, DSMB mid-May, topline 2H 2025 targeting an sNDA to enable at-home IGALMI use — a potentially meaningful label expansion .
  • Operating discipline is working: sharp y/y reductions in R&D and SG&A narrowed net loss; this underpins recent EPS beats despite minimal revenue contribution .
  • Commercial approach remains conservative by design: ongoing “minimal commercial resources” likely caps near-term IGALMI sales; revenue misses vs consensus reflect this stance .
  • Balance sheet stabilized but risk persists: cash of $31.0M post-$14M raise and reverse split/Nasdaq compliance steps are positives; disclosures still flag going-concern and indebtedness risks that investors must monitor .
  • Alzheimer’s dementia program (TRANQUILITY) remains a second leg: FDA inspection closure supports data integrity; plans for In-Care Phase 3 advancing .
  • Model implications: Given management’s focus on clinical milestones and limited commercial spend, near-term revenue estimates may need to remain conservative; EPS sensitivity hinges on OpEx control and financing costs (consensus references marked with asterisks; see S&P Global disclaimer). Actuals from press releases .

S&P Global disclaimer: All consensus/estimate values marked with an asterisk (*) are retrieved from S&P Global.